Page 3«..2345..1020..»


Category Archives: Hypogonadism

LPCN: Tlando: Target Action Date This Friday – Zacks Small Cap Research


Posted: August 25, 2020 at 11:56 pm

By John Vandermosten NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Up and Coming Milestones Tlando PDUFA date August 28, 2020 Primary endpoint results for LiFT (LPCN 1144) 4Q:20 Patent Infringement trial February 2021 Complete Phase II LiFT (LPCN 1144) 2Q:21 Second Quarter 2020 Operational and Financial Results On August 6, 2020 Lipocine (NASDAQ:LPCN) filed its second quarter 2020 10-Q and posted its earnings release for the three month period ending June 30, 2020. The company reported zero revenues and a net loss per share of ($0.13) compared to prior year revenues of zero and loss of ($0.14) per share. Continue reading

Posted in Hypogonadism | Comments Off on LPCN: Tlando: Target Action Date This Friday – Zacks Small Cap Research

UB diabetes expert’s research shows testosterone therapy can lead to remission in men with Type 2 diabetes – UB News Center


Posted: July 30, 2020 at 12:59 pm

BUFFALO, N.Y. Continue reading

Posted in Hypogonadism | Comments Off on UB diabetes expert’s research shows testosterone therapy can lead to remission in men with Type 2 diabetes – UB News Center

Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration – Yahoo Finance


Posted: July 30, 2020 at 12:59 pm

Aytu BioScience's Sublicensee SUDA Pharmaceuticals Secures TGA Approval, Enabling Near-Term Commercialization of ZolpiMist ENGLEWOOD, CO / ACCESSWIRE / July 30, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs, today announced the approval of ZolpiMist (zolpidem tartrate oral spray) by the Therapeutic Goods Administration (TGA) in Australia. This approval, which was secured by the Company's ZolpiMist sublicensee SUDA Pharmaceuticals Ltd ("SUDA"), enables near-term commercialization of ZolpiMist in Australia. Continue reading

Posted in Hypogonadism | Comments Off on Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration – Yahoo Finance

What is Male Menopause? Heres everything you need to know about andropause – PINKVILLA


Posted: July 25, 2020 at 4:55 pm

Andropause or male menopause has to do with the declining hormonal levels in older men. Read on to know the symptoms, causes and treatment of this condition. We often talk about how women suffer from menopause and how it affects their health. Continue reading

Posted in Hypogonadism | Comments Off on What is Male Menopause? Heres everything you need to know about andropause – PINKVILLA

Impact of Covid-19 on Male Hypogonadism market 2020 | What are the key challenges to the Industry growth? – Bulletin Line


Posted: July 25, 2020 at 4:55 pm

Male Hypogonadism Market Industry Forecast To 2026 Garner Insights has titled a new research report named as Male Hypogonadism Market 2020 to its consistently extending database. The report clarifies this through a series of channels which include data ranging from rudimentary data to an undeniable estimate Continue reading

Posted in Hypogonadism | Comments Off on Impact of Covid-19 on Male Hypogonadism market 2020 | What are the key challenges to the Industry growth? – Bulletin Line

Male Hypogonadism Market expected to Witness a Sustainable Growth over 2017 – 2026 – Techinfeed


Posted: July 7, 2020 at 5:59 pm

The global Male Hypogonadism market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Male Hypogonadism market player in a comprehensive way. Continue reading

Posted in Hypogonadism | Comments Off on Male Hypogonadism Market expected to Witness a Sustainable Growth over 2017 – 2026 – Techinfeed

Steroids Know Factors Driving The Market to Record Growth – Daily Research Chronicles


Posted: July 7, 2020 at 5:59 pm

Steroid is an organic compound that has 4 cyclo-alkane rings connected to each other. Steroid consist of 20 carbon atoms. Steroid market is growing owing to increasing demand from the weightlifters and sport industry. Continue reading

Posted in Hypogonadism | Comments Off on Steroids Know Factors Driving The Market to Record Growth – Daily Research Chronicles

Male Hypogonadism Market and Demand for COVID-19 Market Growth Projected to Amplify By 2027 | Eli Lilly and Company, Endo International, Merck &…


Posted: July 4, 2020 at 7:54 pm

Male Hypogonadism Market report provides a thorough synopsis on the study for market and the way its dynamical first rudiment business. This report analyzes the potential of the Market in the present and also the future prospects from numerous angles well Continue reading

Posted in Hypogonadism | Comments Off on Male Hypogonadism Market and Demand for COVID-19 Market Growth Projected to Amplify By 2027 | Eli Lilly and Company, Endo International, Merck &…

No fountain of youth: Just because theres a way to boost testosterone doesnt mean you should, experts warn – Gadsden Times


Posted: June 25, 2020 at 8:52 am

Testosterone therapy ads promise to help aging men recapture their vitality, decrease body fat and enhance libido. But hormone treatments while medically necessary for some men arent meant to be a fountain of youth, and experts warn more research is needed to determine if such therapy could boost heart disease risks. Testosterone levels naturally decline in most men as they age Continue reading

Posted in Hypogonadism | Comments Off on No fountain of youth: Just because theres a way to boost testosterone doesnt mean you should, experts warn – Gadsden Times

QOL and body composition benefits seen with novel oral T treatment – Urology Times


Posted: June 15, 2020 at 1:58 am

New data from phase 3 clinical trials provide further evidence supporting the safety and effectiveness of the first-to-market oral testosterone undecanoate treatment for hypogonadism (Jatenzo), reported Stanton Honig, MD. Honig presented results for secondary end points from 2 randomized studies comparing the lipoprotein-coated testosterone undecanoate formulation with topical testosterone treatments showing that both the oral and gel products were associated with statistically significant improvements in psychosocial well-being and bone and body composition parameters Continue reading

Posted in Hypogonadism | Comments Off on QOL and body composition benefits seen with novel oral T treatment – Urology Times

Page 3«..2345..1020..»